**SAFEGUARDRX®** 

# Oncology Care Value® Program



We all know someone whose life has been impacted by a cancer diagnosis: a single disease class that takes many forms, affects every patient differently, and disrupts millions of lives physically, emotionally and financially every year. It knows no bounds, taking hold of men and women across ages, races and demographics.

With an estimated 1.9 million new diagnoses in 2021, and over 17 million Americans currently battling cancer today, the impacts of this disease are far-reaching. 1.2 Given the delays in accessing preventative care and maintaining routine screenings since 2020, we are going to see a significant rise in advanced-stage cancers over the next few years. 3



National health care costs associated with cancer treatment are expected to rise 34% by 2030, totaling \$246 BILLION IN

ANNUAL SPEND<sup>5</sup>

# TREATMENTS ARE COSTLY FOR EVERYONE

Significant investments and innovations have been made to advance oncology medications and improve mortality rates.

While new oncology medications offer patients more treatment options, the cost of these medications represents an ever-growing challenge to our health care system, your benefits budget and your members' financial stability.

With an average cost per prescription of \$10,150, you and your members are facing a massive financial strain when they receive a positive diagnosis and start treatment.<sup>4</sup>

## **ALIGNING TREATMENTS WITH OUTCOMES**

It can be impossible to know how each patient will respond to therapy. Sometimes, patients are prescribed a therapy that doesn't work as well for their specific type of cancer, and many are moved from one regimen to another. Often faced with progressing diagnoses, cancer patients have little time to waste on therapy changes.

### A BETTER FUTURE FOR ALL

The Oncology Care Value program has been supporting plans and patients since 2016 by aligning medication costs with their outcomes for various types of cancers, while offering drug discounts and early discontinuation reimburs ements to plan sponsors. The program also ensures that members have access to personalized

The Oncology Care Value program is part of the SafeGuardRx portfolio that helps save lives and money by focusing on the most costly and complex conditions. We're excited to bring these solutions to you as Evernorth <sup>SM</sup>, leveraging the specialized clinical model and value-based contracting strategies from Express Scripts PBM.



medicine—that they have access to the right drug at the right time. In fact, in 2021, enrolled plans saw \$1.9M in cost savings.<sup>4</sup>

# **HOW IT WORKS**



Cost savings on expensive oncology medications when filled at Accredo® Specialty Pharmacy. Further savings are realized with our early discontinuation reimbursement for non-small cell lung cancer patients who stop treatment early.



**Specialized care** from the Accredo Oncology Therapeutic Resource Center<sup>SM</sup>.



**Personalized medicine** through genetic testing for chronic myeloid leukemia patients puts even more information in the patient's and the physician's hands, allowing them to work together to optimize the treatment journey, avoid adverse drug events, improve health outcomes and drive savings.



**Indication-based management** aligns drug cost based on efficacy at the indication level, so you and your members are paying fair drug prices for guideline-driven therapy.





For more information about the Oncology Care Value program and how SafeGuardRx makes medicine work harder, visit <u>SafeGuardRx.com</u> or contact your account representative.

- 1. Cancer.org, Cancer Facts & Figures 2021
- 2. National Cancer Institute
- 3. American Cancer Society Journals, Impact of the COVID-19 pandemic on diagnosis of new cancers
- 4. 2021 Express Scripts Data
- 5. American Association for Cancer Research

### About SafeGuardRx

SafeGuardRx offers protection from health care's biggest budgetary threats by combining multiple effective cost-containment strategies into a single platform, and enrolled plans experience lower overall trend than nonenrolled plans. Paired with condition-specific patient engagement and support clients see better patient medication adherence, higher therapy completion rates and greater compliance with clinical guidelines.



